Optherion is Drug Discovery in United States that focus on hemolytic uremic syndrome business. Founded in 2005. They cover business area such as developer, product, age relate macular degeneration, diagnostic and disease-modify therapeutic, treatment, early-stage age-relate macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome.
2005
( 19 years old in 2024 )
Hemolytic Uremic Syndrome
-
11th Floor 555 Long Wharf Drive
The Maritime Center
New Haven, CT 06511
United States
Private
developerproductage relate macular degenerationdiagnostic and disease-modify therapeutictreatmentearly-stage age-relate macular degenerationdense deposit diseaseatypical hemolytic uremic syndrome
* We use standard office opening hours in near Optherion's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Optherion is Drug Discovery business from United States that founded in 2005 (19 years old in 2024), Optherion business is focusing on Hemolytic Uremic Syndrome.
Optherion headquarter office and corporate office address is located in 11th Floor 555 Long Wharf Drive The Maritime Center New Haven, CT 06511 United States.
Optherion was founded in United States.
In 2024, Optherion is currently focus on hemolytic uremic syndrome sector.
Above is snippet of Google Trends for "hemolytic uremic syndrome" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Optherion, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
